Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02199236 · ClinicalTrials.gov registry record · Phase 1
Dose Escalation Trial of Endoluminal High-Dose-Rate Brachytherapy With Concurrent Chemotherapy for Rectal or Anal Cancer in Patients With Recurrent Disease or Undergoing Non-Operative Management
A Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT02199236: Completed Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT02199236 is a Phase 1 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 15 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02199236, a Phase 1 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
The purpose of this study is to see what amount of radiation is safe to give to rectal or anal cancer patients who are being treated with a procedure called brachytherapy.
Interventions
- BEHAVIORAL Questionnaires
- RADIATION endorectal brachytherapy
- DRUG concurrent capecitabine or 5-FU
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2014-07 |
| Est. Completion | 2024-10-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02199236
The ClinicalTrials.gov registry entry for NCT02199236 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Questionnaires is the first listed.
NCT02199236 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02199236 about?
NCT02199236 is a clinical study titled "Dose Escalation Trial of Endoluminal High-Dose-Rate Brachytherapy With Concurrent Chemotherapy for Rectal or Anal Cancer in Patients With Recurrent Disease or Undergoing Non-Operative Management". The purpose of this study is to see what amount of radiation is safe to give to rectal or anal cancer patients who are being treated with a procedure called brachytherapy.
What is the current status of trial NCT02199236?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2014-07. Estimated completion is 2024-10-29.
What interventions are being tested in trial NCT02199236?
The interventions under investigation include: Questionnaires (BEHAVIORAL), endorectal brachytherapy (RADIATION), concurrent capecitabine or 5-FU (DRUG).
Who is sponsoring clinical trial NCT02199236?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.